You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 8, 2024

Bausch Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Bausch
International Patents:772
US Patents:121
Tradenames:155
Ingredients:122
NDAs:176
Patent Litigation for Bausch: See patent lawsuits for Bausch

Drugs and US Patents for Bausch

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No 7,645,802 ⤷  Try a Trial Y ⤷  Try a Trial
Bausch And Lomb Inc OLOPATADINE HYDROCHLORIDE olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206087-001 Dec 5, 2017 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Bausch VASOTEC enalapril maleate TABLET;ORAL 018998-005 Jul 26, 1988 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Bausch And Lomb Inc MIEBO perfluorohexyloctane SOLUTION/DROPS;OPHTHALMIC 216675-001 May 18, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bausch

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 5,288,505 ⤷  Try a Trial
Bausch TARGRETIN bexarotene GEL;TOPICAL 021056-001 Jun 28, 2000 6,320,074 ⤷  Try a Trial
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 6,685,958 ⤷  Try a Trial
Bausch And Lomb Inc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 6,113,906 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Solution 10% ➤ Subscribe 2018-06-06
➤ Subscribe Cream 0.10% ➤ Subscribe 2008-01-31
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Cream 2.5% ➤ Subscribe 2014-06-17
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 2005-08-30
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 2004-03-23
➤ Subscribe Extended-release Tablets 65 mg and 115 mg ➤ Subscribe 2009-11-19
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 2008-12-23
➤ Subscribe Extended-release Tablet 105 rng ➤ Subscribe 2010-12-28
➤ Subscribe Gel 1.2%/3.75% ➤ Subscribe 2015-09-30
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2012-10-19
➤ Subscribe Gel 0.04% ➤ Subscribe 2010-12-20
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09
➤ Subscribe Gel 1.2%/0.025% ➤ Subscribe 2010-12-17
➤ Subscribe Gel 0.77% ➤ Subscribe 2006-05-10
➤ Subscribe Lotion 0.1% ➤ Subscribe 2016-08-31
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Cream 3.75% ➤ Subscribe 2012-08-08
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24
➤ Subscribe For Inhalation Solution 6 gm/vial ➤ Subscribe 2014-05-22
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 2005-04-25
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 2008-12-08
➤ Subscribe Extended-release Tablet 55 mg and 80 mg ➤ Subscribe 2010-12-02
➤ Subscribe Gel 1.2%/2.5% ➤ Subscribe 2012-12-20
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 2004-09-21
➤ Subscribe Gel 0.1% ➤ Subscribe 2010-07-08
➤ Subscribe Ophthalmic Solution 0.07% ➤ Subscribe 2013-07-26
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Vaginal Gel 0.75% ➤ Subscribe 2004-09-02
➤ Subscribe Cream 5% ➤ Subscribe 2006-10-17

Supplementary Protection Certificates for Bausch Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1856135 CR 2020 00018 Denmark ⤷  Try a Trial PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
1458369 SPC/GB10/005 United Kingdom ⤷  Try a Trial PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1280520 122015000021 Germany ⤷  Try a Trial PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
0957929 PA2006004 Lithuania ⤷  Try a Trial PRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.